|[April 16, 2014]
Mölnlycke Health Care AB: A World First: Preventing Skin Reactions During Radiation Therapy
STOCKHOLM --(Business Wire)--
A study published in the Radiotherapy & Oncology Journal has shown that
the use of Mepitel Film® dressings prevents the development of moist
desquamation: painful skin ulcerations associated with breast cancer
radiation therapy. The study also found that the same dressing reduced
the overall severity of skin reactions such as itching and irritation by
Radiation-induced skin reactions occur in 80-90% of breast cancer
patients and can range from mild redness to ulceration, with symptoms of
pain, burning and itchiness. This can have a very negative impact on day
to day life for patients, who already have to cope with being diagnosed
with and treated for cancer.
Until now, creams, gels and dressings have been used to reduce these
severe side effects, but none have been able to completely prevent them.
A study conducted in New Zealand has shown that the use of MepitelFilm,
a thin, transparent dressing using Mölnlycke Health Care's
Safetac®technology, before, during and after radiation therapy, prevents
the development of moist desquamation and reduces the severity of other
78 patients undergoing radiation therapy for breast cancer took part in
the trial. Each patient's irradiated skin area was divided into two
halves, with Mepitel Film used on one side and aqueous cream on the
other. The study found that there were no cases of ulceration or severe
skin reactions on the skin under Mepitel Film, whilst cream-treated skin
developed these wounds in 26% of patients. In addition, the skin
reactions that did develop under Mepitel Film wer 92% less severe than
in the cream-treated control group.
Dr. Patries Herst, a senior lecturer at the Department of Radiation
Therapy at the University of Otago and principal investigator for the
"I am absolutely delighted with the results! We finally have a product
that really works; this is fantastic news for cancer patients."
Phil Cooper, President of Mölnlycke Health Care's Wound Care Division,
"The dermatological side effects associated with radiation therapy can
be very severe. Not only do they cause physical suffering, but also
impact the lives of patients, limiting the clothes they can wear and
activities they can engage in.
"By using a transparent, thin and pain-free dressing, patients can
drastically improve their quality of life during and after treatment. I
know I speak on behalf of all of my colleagues when I say that we are
very proud to be involved in making that possible."
1. Herst PM et al. Prophylactic use of Mepitel Film prevents
radiation-induced moist desquamation in an intra-patient randomised
controlled clinical trial of 78 breast cancer patients. Radiother Oncol
2. Wells M (2003) Radiation skin reactions. Faithfull S (Ed) Supportive
care in radiotherapy. London: Churchill Livingstone 135-159.
Mölnlycke Health Care is a world leading manufacturer of wound care and
single-use surgical products and a service provider to the healthcare
Headquartered in Göteborg, Sweden, Mölnlycke Health Care's history dates
back to 1849, when it was founded as a textile manufacturer. The Company
became independent in 1997 and since 2007 is majority-owned by Investor
AB. The Company has over 7,400 employees across over 30 countries.
The Wound Care Division offers gentle and effective wound care
solutions. Featured products include those with the unique and patented
Safetac®technology that reduce unnecessary suffering during a patient's
wound healing journey. Safetac®is available exclusively on Mepitel®,
Mepilex®and other selected dressings.
This information was brought to you by Cision http://news.cision.com
[ Back To TMCnet.com's Homepage ]